KR102513994B1 - Composition for preventing tear staining of companion animals - Google Patents
Composition for preventing tear staining of companion animals Download PDFInfo
- Publication number
- KR102513994B1 KR102513994B1 KR1020220139093A KR20220139093A KR102513994B1 KR 102513994 B1 KR102513994 B1 KR 102513994B1 KR 1020220139093 A KR1020220139093 A KR 1020220139093A KR 20220139093 A KR20220139093 A KR 20220139093A KR 102513994 B1 KR102513994 B1 KR 102513994B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- powder
- companion animals
- composition
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 238000010186 staining Methods 0.000 title claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 89
- 235000020251 goat milk Nutrition 0.000 claims abstract description 15
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims abstract description 13
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims abstract description 13
- 235000005881 Calendula officinalis Nutrition 0.000 claims abstract description 12
- 240000000785 Tagetes erecta Species 0.000 claims abstract description 12
- 210000003022 colostrum Anatomy 0.000 claims abstract description 12
- 235000021277 colostrum Nutrition 0.000 claims abstract description 12
- 240000000599 Lentinula edodes Species 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 12
- 239000008213 purified water Substances 0.000 claims description 11
- 240000007124 Brassica oleracea Species 0.000 claims description 9
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 9
- 229940069780 barley extract Drugs 0.000 claims description 8
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 6
- 235000000832 Ayote Nutrition 0.000 claims description 5
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims description 5
- 240000004244 Cucurbita moschata Species 0.000 claims description 5
- 235000009854 Cucurbita moschata Nutrition 0.000 claims description 5
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims description 5
- 244000000626 Daucus carota Species 0.000 claims description 5
- 235000002767 Daucus carota Nutrition 0.000 claims description 5
- 102000002322 Egg Proteins Human genes 0.000 claims description 5
- 108010000912 Egg Proteins Proteins 0.000 claims description 5
- 244000017020 Ipomoea batatas Species 0.000 claims description 5
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 5
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 5
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 5
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 210000003278 egg shell Anatomy 0.000 claims description 5
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 5
- 235000008390 olive oil Nutrition 0.000 claims description 5
- 239000004006 olive oil Substances 0.000 claims description 5
- 235000015136 pumpkin Nutrition 0.000 claims description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 4
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 4
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 4
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 4
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 4
- 229960002733 gamolenic acid Drugs 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 3
- 241000289667 Erinaceus Species 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 235000013793 astaxanthin Nutrition 0.000 claims description 3
- 239000001168 astaxanthin Substances 0.000 claims description 3
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 3
- 229940022405 astaxanthin Drugs 0.000 claims description 3
- -1 glycerin fatty acid ester Chemical class 0.000 claims description 3
- 229960001047 methyl salicylate Drugs 0.000 claims description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 9
- 239000003963 antioxidant agent Substances 0.000 abstract description 9
- 239000012141 concentrate Substances 0.000 abstract description 8
- 230000001976 improved effect Effects 0.000 abstract description 6
- 239000000049 pigment Substances 0.000 abstract description 6
- 150000004032 porphyrins Chemical class 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 102000010445 Lactoferrin Human genes 0.000 abstract description 5
- 108010063045 Lactoferrin Proteins 0.000 abstract description 5
- 210000003743 erythrocyte Anatomy 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000010438 iron metabolism Effects 0.000 abstract description 5
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract description 5
- 229940078795 lactoferrin Drugs 0.000 abstract description 5
- 235000021242 lactoferrin Nutrition 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 5
- 239000007787 solid Substances 0.000 abstract description 5
- 240000005979 Hordeum vulgare Species 0.000 abstract description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 abstract description 4
- 235000008504 concentrate Nutrition 0.000 abstract description 4
- 230000004438 eyesight Effects 0.000 abstract description 3
- 244000308180 Brassica oleracea var. italica Species 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 206010013774 Dry eye Diseases 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 208000003464 asthenopia Diseases 0.000 description 5
- 208000030533 eye disease Diseases 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 description 4
- 206010048673 Tear discolouration Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940010747 sodium hyaluronate Drugs 0.000 description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002314 glycerols Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- XUDNWQSXPROHLK-OACYRQNASA-N 2-phenyl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC=CC=2)OC2=CC=CC=C2C1=O XUDNWQSXPROHLK-OACYRQNASA-N 0.000 description 1
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 1
- HGUVPEBGCAVWID-KETMJRJWSA-N 7-O-(beta-D-glucosyl)isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-KETMJRJWSA-N 0.000 description 1
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 235000021144 fermentable dietary fiber Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 1
- 235000011576 oleuropein Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229960001109 policosanol Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- HGUVPEBGCAVWID-UHFFFAOYSA-N saponarin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)C2C(C(O)C(O)C(CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-UHFFFAOYSA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 반려동물의 눈물 착색예방용 조성물에 관한 것으로, 보다 상세하게는 브로콜리 스프라우트 고형물과 분말, 새싹보리 분말또는 농축액, 산양유 및 초유 추출물 락토페린 분말, 표고버섯 균사체 분말, 마리골드추출물 분말 또는 농축액을 유효 성분으로 하여 항산화에 따른 염증 저감, 눈의 시각 형성을 담당하는 황반색소의 밀도를 증가시키고 철분 대사를 늘려 적혈구의 분해로 인해 생성되는 포르피린의 분비를 억제하여 적색 눈물을 예방할 수 있도록 개선된 반려동물의 눈물 착색예방용 조성물에 관한 것이다.The present invention relates to a composition for preventing tear discoloration of companion animals, and more particularly, broccoli sprout solids and powder, barley sprout powder or concentrate, goat milk and colostrum extract lactoferrin powder, shiitake mushroom mycelium powder, marigold extract powder or concentrate as an active ingredient to reduce inflammation due to antioxidants, increase the density of the macular pigment responsible for the visual formation of the eye, and increase iron metabolism to suppress the secretion of porphyrin produced by the decomposition of red blood cells to prevent red tears. It relates to a composition for preventing tear discoloration of companion animals.
애완동물은 사람들이 좋아하여 가까이 두고 귀여워하며 기르는 동물을 말하며, 개, 고양이, 새, 금붕어 등을 포함한다. Pets refer to animals that people like, keep close to, and keep, and include dogs, cats, birds, goldfish, and the like.
이중에서 개와 고양이 등의 일부 애완동물은 개인화된 현대 사회에서 주인과 삶을 함께하며 감정적 교감을 나누는 반려동물로서 그 역할을 확장해 가고 있으며, 최근에는 개와 고양이뿐만 아니라 앵무새, 고슴도치, 토끼 및 햄스터 등까지 그 종류가 다양해지고 있고, 그에 따른 관련 산업도 급속도로 발전하고 있다.Among them, some pets, such as dogs and cats, are expanding their roles as companion animals that live with their owners and share emotional sympathy in a personalized modern society. Its types are diversifying, and related industries are also developing rapidly.
일 예로, 반려동물의 사료나 간식이 단순히 영양 성분을 공급하기 위한 수단에서 벗어나 각종 기능성 성분을 함유하여 반려동물의 건강을 증진시킬 뿐만 아니라 기호도에 맞게 식감이나 향 등이 개선된 제품들을 들 수 있다.For example, food or snacks for companion animals are not simply a means of supplying nutrients, but contain various functional ingredients to improve the health of companion animals, as well as products with improved texture or flavor according to preference. .
한편, 영양공급이나 질병관리가 확대되어 반려동물의 수명이 점차 향상되고 있는데, 반려동물의 수명 향상에 따라 눈 질환이나 노화에 따른 시력저하 등이 발생하고 있다.On the other hand, the lifespan of companion animals is gradually improving due to the expansion of nutrition supply or disease management. As the lifespan of companion animals improves, eye diseases or vision loss due to aging are occurring.
하지만, 이를 개선하기 위한 사료, 간식 및 영양제 등의 개발은 미진한 상태이다.However, the development of feed, snacks, and nutritional supplements to improve this is insufficient.
물론, 하기한 [선행기술문헌]과 같은 특허기술이 개시되기도 하였지만, 반려동물, 그 중에서도 특히 강아지(개)의 눈 관리와 관련하여 사용자의 접근 편의성(사용 편리성)을 좋게 하고 저렴한 비용으로 제조할 수 있는 다양한 제품들이 개발되어야 하므로 그 일환으로 개발의 필요성이 지속적으로 요청되고 있다.Of course, patent technologies such as the following [Prior Art Literature] have been disclosed, but in relation to eye care of companion animals, especially puppies (dogs), the user's access convenience (use convenience) is improved and manufactured at low cost. As various products that can do this must be developed, the need for development is continuously requested as part of it.
즉, 제품을 다양화시켜 소비자의 선택폭을 넓힐 필요성이 제기되었다.In other words, the need to diversify products to broaden the range of choices for consumers has been raised.
본 발명은 상술한 바와 같은 종래 기술상의 제반 문제점들을 감안하여 이를 해결하고자 창출된 것으로, 브로콜리 스프라우트 고형물과 분말, 새싹보리 분말또는 농축액, 산양유 및 초유 추출물 락토페린 분말, 표고버섯 균사체 분말, 마리골드추출물 분말 또는 농축액을 유효 성분으로 하여 항산화에 따른 염증 저감, 눈의 시각 형성을 담당하는 황반색소의 밀도를 증가시키고 철분 대사를 늘려 적혈구의 분해로 인해 생성되는 포르피린의 분비를 억제하여 적색 눈물을 예방할 수 있도록 개선된 반려동물의 눈물 착색예방용 조성물를 제공함에 그 주된 목적이 있다.The present invention was created to solve these problems in view of the various problems in the prior art as described above, broccoli sprout solids and powder, sprout barley powder or concentrate, goat milk and colostrum extract lactoferrin powder, shiitake mushroom mycelium powder, marigold extract Powder or concentrate is used as an active ingredient to reduce inflammation due to antioxidants, increase the density of macular pigment, which is responsible for forming the visual field of the eye, and increase iron metabolism to prevent red tears by suppressing the secretion of porphyrins produced by the decomposition of red blood cells. Its main purpose is to provide a composition for preventing tear staining of companion animals that has been improved to
본 발명은 상기한 목적을 달성하기 위한 수단으로, 정제수 100중량부에 대해, 브로콜리 스프라우트 분말 40-50중량부, 새싹보리 추출물 분말 30-40중량부, 산양유(초유 포함) 추출물 분말 20-30중량부, 표고버섯균사체 분말 30-40중량부, 마리골드 추출물 분말 10-20중량부를 포함하는 것을 특징으로 하는 반려동물의 눈물 착색예방용 조성물을 제공한다.The present invention is a means for achieving the above object, based on 100 parts by weight of purified water, 40-50 parts by weight of broccoli sprout powder, 30-40 parts by weight of sprout barley extract powder, 20-30 parts by weight of goat milk (including colostrum) extract powder It provides a composition for preventing tear staining of companion animals, comprising 30-40 parts by weight of shiitake mushroom mycelium powder and 10-20 parts by weight of marigold extract powder.
본 발명에 따르면, 브로콜리 스프라우트 고형물과 분말, 새싹보리 분말또는 농축액, 산양유 및 초유 추출물 락토페린 분말, 표고버섯 균사체 분말, 마리골드추출물 분말 또는 농축액을 유효 성분으로 하여 항산화에 따른 염증 저감, 눈의 시각 형성을 담당하는 황반색소의 밀도를 증가시키고 철분 대사를 늘려 적혈구의 분해로 인해 생성되는 포르피린의 분비를 억제하여 적색 눈물을 예방할 수 있도록 개선된 효과를 얻을 수 있다.According to the present invention, broccoli sprout solids and powder, sprouted barley powder or concentrate, goat milk and colostrum extract lactoferrin powder, shiitake mushroom mycelium powder, marigold extract powder or concentrate are used as active ingredients to reduce inflammation due to antioxidants, visual acuity of the eyes By increasing the density of macular pigment responsible for formation and increasing iron metabolism, it is possible to obtain an improved effect to prevent red tears by inhibiting the secretion of porphyrins produced by the decomposition of red blood cells.
도 1은 본 발명에 따른 조성물을 강아지에 급여하여 눈물 착색 면적이 감소하는지 여부를 측정하는 실험 대상 강아지에 대한 사진이다.
도 2는 도 1의 실험 대상 강아지 중 강아지2,3,4,7에 대해 눈 주변 털의 습윤 정도를 거즈로 닦아내어 축축해지는 면적, 점도, 착색강도를 확인한 사진이다.1 is a photograph of a test subject puppies measuring whether or not the tear staining area is reduced by feeding the composition according to the present invention to the puppies.
Figure 2 is a photograph confirming the wet area, viscosity, and coloring strength of puppies 2, 3, 4, and 7 among the experimental puppies of FIG. 1 by wiping the wetness level of the fur around the eyes with gauze.
이하에서는, 첨부도면을 참고하여 본 발명에 따른 바람직한 실시예를 보다 상세하게 설명하기로 한다.Hereinafter, preferred embodiments according to the present invention will be described in more detail with reference to the accompanying drawings.
본 발명 설명에 앞서, 이하의 특정한 구조 내지 기능적 설명들은 단지 본 발명의 개념에 따른 실시예를 설명하기 위한 목적으로 예시된 것으로, 본 발명의 개념에 따른 실시예들은 다양한 형태로 실시될 수 있으며, 본 명세서에 설명된 실시예들에 한정되는 것으로 해석되어서는 아니된다.Prior to the description of the present invention, the following specific structural or functional descriptions are only exemplified for the purpose of explaining embodiments according to the concept of the present invention, and embodiments according to the concept of the present invention may be implemented in various forms, It should not be construed as limited to the embodiments described herein.
본 발명에 따른 반려동물의 눈물 착색예방용 조성물은 브로콜리 스프라우트 분말, 새싹보리 추출물 분말, 산양유(초유 포함) 추출물 분말, 표고버섯균사체 분말, 마리골드 추출물 분말을 유효성분으로 포함한다.The composition for preventing tear discoloration of companion animals according to the present invention includes broccoli sprout powder, sprout barley extract powder, goat milk (including colostrum) extract powder, shiitake mushroom mycelium powder, and marigold extract powder as active ingredients.
그리하여, 이들 조성물을 정제수에 괴어 분말이나 액상 또는 타블렛(Tablet) 형태로 만들어 반려동물, 특히 강아지에게 급여할 수 있다.Thus, these compositions can be soaked in purified water and made into powder, liquid or tablet form and fed to companion animals, especially puppies.
이러한 조성물은 세균, 바이러스에 의해 일반적으로 감염되는 반려동물, 특히 강아지의 결막염, 각막염, 이로 인한 안구건조증 등을 예방하고 개선시키는데 있어 도움을 주는 특징이 있다.These compositions are characterized by helping to prevent and improve conjunctivitis, keratitis, dry eye syndrome, etc. of companion animals commonly infected by bacteria and viruses, in particular dogs.
보다 구체적으로, 본 발명에 따른 조성물은 정제수 100중량부에 대해, 브로콜리 스프라우트 분말 40-50중량부, 새싹보리 추출물 분말 30-40중량부, 산양유(초유 포함) 추출물 분말 20-30중량부, 표고버섯균사체 분말 30-40중량부, 마리골드 추출물 분말 10-20중량부를 포함한다.More specifically, the composition according to the present invention is based on 100 parts by weight of purified water, 40-50 parts by weight of broccoli sprout powder, 30-40 parts by weight of sprout barley extract powder, 20-30 parts by weight of goat milk (including colostrum) extract powder, It contains 30-40 parts by weight of shiitake mushroom mycelium powder and 10-20 parts by weight of marigold extract powder.
여기에서, 브로콜리 스프라우트 분말은 항산화 물질인 베타카로틴, 플라보놀 배당체 루틴, 셀레늄, 결정성 폴리펩티드 글루타티온, 퀘르세틴을 다량 함유하고 있어 함유된 항산화물질로 인해 결막염, 각막염, 포도막염등의 각종 염증성질환을 예방하여 강아지의 눈 건강을 유지하는데 기여한다.Here, broccoli sprout powder contains a large amount of antioxidants such as beta-carotene, flavonol glycoside rutin, selenium, crystalline polypeptide glutathione, and quercetin, which prevent various inflammatory diseases such as conjunctivitis, keratitis, and uveitis due to the antioxidants contained. This contributes to maintaining the dog's eye health.
또한, 새싹보리 추출물 분말은 항산화 물질로서 항염기능을 갖는 사포나린, 루토나린, 이이소비텍신 등 기능성 이차 대사물질 및 대사증후군에 효과적인 폴리코사놀 등이 함유되어 있어 미네랄등의 기능성 대사를 원활하게 하고 철분흡수를 도와 포르피린 양 감소에 도움을 주어 눈물 착색을 예방하고, 눈 건강을 유지시키는데 기여하게 된다.In addition, sprouted barley extract powder contains functional secondary metabolites such as saponarin, rutonarin, and isosorbidexin, which have anti-inflammatory functions as antioxidants, and policosanol, which is effective for metabolic syndrome, so that functional metabolism such as minerals is smooth and iron absorption is improved. It helps to reduce the amount of porphyrin, thereby preventing tear staining and contributing to maintaining eye health.
특히, 새싹보리 추출물은 발효성 식이섬유가 풍부하여 필수미네랄인 칼슘, 인, 포타슘, 아연, 철분, 마그네슘 등의 흡수와 대사 이용율을 높여 눈물착색물질인 포르피린양 감소에 도움을 주고, 눈 건강을 유지시키는 장점이 있다.In particular, sprout barley extract is rich in fermentable dietary fiber, so it increases the absorption and metabolic utilization rate of essential minerals calcium, phosphorus, potassium, zinc, iron, magnesium, etc. There are advantages to keeping it.
그리고, 초유를 포함한 산양유 추출물은 항바이러스성과 항균성을 띈 락토페린을 주성분으로 한 분말로서 철분과의 결합성을 높여 감염억제, 눈 조직 손상을 방지하여 눈의 피로도를 낮추고 눈 건강을 회복하는데 기여하게 된다.In addition, goat milk extract, including colostrum, is a powder whose main component is lactoferrin, which has antiviral and antibacterial properties. It increases the binding with iron to inhibit infection and prevent eye tissue damage, thereby reducing eye fatigue and contributing to restoring eye health. .
무엇보다도, 반려동물, 특히 강아지가 적색 눈물을 흘린 경우 이는 적혈구가 분해될 때 생성되는 포르피린이 눈물과 타액으로 배출되는 현상으로 철분 대사가 부족한 경우 주로 발생하므로, 본 발명에서는 붉은 단백질인 락토페린이 철분과 결합하여 철분의 강아지 체내 흡수 및 대사를 활성화시켜 눈물 착색이나 적색 눈물 분비를 억제하게 된다.Above all, when a companion animal, especially a puppy, sheds red tears, this is a phenomenon in which porphyrins produced when red blood cells are decomposed are discharged into tears and saliva, which mainly occurs when iron metabolism is insufficient. Combined with, it activates the absorption and metabolism of iron in the dog's body, suppressing the secretion of tear color or red tears.
뿐만 아니라, 표고버섯균사체 분말은 항산화 물질로서 세균 감염에 대한 저항력과 면역관련 지표 개선에 도움을 주는 알파글루칸과 베타글루칸이 포함되어 있어 각막염, 결막염 및 포도막염등의 안질환을 예방 및 개선하는데 도움을 준다.In addition, shiitake mushroom mycelium powder contains alpha-glucan and beta-glucan, which are antioxidants that help improve resistance to bacterial infection and immune-related indicators, helping to prevent and improve eye diseases such as keratitis, conjunctivitis, and uveitis. give.
아울러, 마리골드 추출물은 카로티노이드계 색소인 루테인이 다량 함유되어 있어 황반변성의 반려동물 안과 질환을 개선하는데 도움을 주는 것으로 보고되어 있으며, 특히 항산화효과와 면역활성력이 우수한 것으로 알려져 있다.In addition, it is reported that marigold extract contains a large amount of lutein, a carotenoid-based pigment, to help improve ophthalmic diseases of macular degeneration, and is known to have excellent antioxidant effects and immune activity.
즉, 마리골드 추출물에 다량 함유된 루테인은 강아지의 황반색소 밀도를 증가시키고, 동시에 노화로 인한 황반 퇴행성도 감소시켜 눈의 시각 능력이 떨어지는 것을 억제하여 건강한 눈 활동을 유지할 수 있도록 조력하게 된다.That is, lutein contained in a large amount of marigold extract increases the density of macular pigment in dogs, and at the same time reduces macular degeneration due to aging, thereby suppressing the decline in visual ability of the eyes and helping to maintain healthy eye activity.
이때, 본 발명에서는 산양유(초유 포함) 추출물에 류신(Leucine)과 감마리놀렌산을 더 함유시켜 눈 주변의 근손실을 억제하고, 강아지의 안구건조 현상을 억제하는데 도움을 줄 수 있다.At this time, in the present invention, by further containing leucine and gamma linolenic acid in the goat milk (including colostrum) extract, it can help to suppress muscle loss around the eyes and suppress dry eye phenomenon in dogs.
이 경우, 상기 류신과 감마리놀렌산은 상기 산양유 추출물 100중량부를 기준으로 5.5중량부 및 3.5중량부를 각각 첨가 혼합함이 바람직하다.In this case, it is preferable to add and mix 5.5 parts by weight and 3.5 parts by weight of the leucine and gamma-linolenic acid, respectively, based on 100 parts by weight of the goat milk extract.
또한, 본 발명에서는 상기 정제수 100중량부에 대해, 메틸살리실레이트 10중량부, N-아세틸글루코사민 15중량부를 더 첨가할 수 있다.In the present invention, 10 parts by weight of methyl salicylate and 15 parts by weight of N-acetylglucosamine may be further added to 100 parts by weight of the purified water.
여기에서, 메틸살리실레이트(Methyl Salicylate)는 눈 근육을 풀어주고, 근육에 대한 소염 진정 및 소화작용을 촉진하기 위해 첨가된다.Here, methyl salicylate is added to relax the eye muscles and promote anti-inflammatory soothing and digestive effects on the muscles.
그리고, N-아세틸글루코사민(N-acetyl glucosamine)은 갑각류의 껍데기에서 나온 화학물질로서 히알루론산의 생성을 자극하여 각막염이나 결막염을 예방하고, 각막 통증을 완화시키는 효과가 있는 것으로 보고되어 있다.And, N-acetyl glucosamine (N-acetyl glucosamine) is a chemical substance from the shells of crustaceans and has been reported to be effective in stimulating the production of hyaluronic acid to prevent keratitis or conjunctivitis and alleviate corneal pain.
뿐만 아니라, 본 발명은 브로콜리 스프라우트 분말 100중량부에 대해, 카르복시메틸 셀룰로오스나트륨 10중량부, 글리세린지방산에스테르 10중량부, 뜨레할로스액 5중량부, 징코라이드 5중량부, 아스타잔틴 2.5중량부, 감마 아미노뷰티르산 3.5중량부를 더 첨가할 수 있다.In addition, the present invention is based on 100 parts by weight of broccoli sprout powder, 10 parts by weight of sodium carboxymethyl cellulose, 10 parts by weight of glycerin fatty acid ester, 5 parts by weight of trehalose solution, 5 parts by weight of zincolide, 2.5 parts by weight of astaxanthin Part, 3.5 parts by weight of gamma aminobutyric acid may be further added.
이때, 카르복시메틸 셀룰로오스나트륨(Sodium Carboxymethyl Cellulose)은 수용성인 셀룰로오스로서 물에 녹아 눈꺼풀 표면에서의 가려움, 이물감을 억제하게 된다.At this time, sodium carboxymethyl cellulose (Sodium Carboxymethyl Cellulose) is water-soluble cellulose and dissolves in water to suppress itchiness and foreign body sensation on the surface of the eyelids.
그리고, 글리세린지방산에스테르(Glycerin Esters of Fatty Acids)는 눈 자극을 억제하여 눈의 피로도를 줄여 주고 눈물샘이 막히는 것을 억제하는 작용을 한다.In addition, glycerin esters of fatty acids (Glycerin Esters of Fatty Acids) suppress eye irritation, reduce eye fatigue, and act to suppress clogging of tear glands.
특히, 뜨레할로스(Trehalose)는 포도당 2분자로 구성된 이당류로서, 물에 녹인 액상으로 사용되며, 감미성을 향상시키고 pH를 안정화시킨다.In particular, trehalose is a disaccharide composed of two molecules of glucose, and is used as a liquid dissolved in water to improve sweetness and stabilize pH.
또한, 징코라이드는 피로인산게라닐게라닐(geranylgeranyl pyrophosphate)로부터 합성되는 20개의 탄소골격을 갖는 물질로서, 보통은 심혈관개선제로 사용되지만, 본 발명에서는 눈의 피로도를 해소하고 개선하는 기능으로 활용된다.In addition, zincolide is a substance with a 20-carbon skeleton synthesized from geranylgeranyl pyrophosphate, and is usually used as a cardiovascular improvement agent, but in the present invention, it is used as a function to relieve and improve eye fatigue. .
아울러, 아스타잔틴은 비타민C보다 무려 6000배나 항산화 능력이 있어 눈의 피로도를 풀고, 눈 건강에 도움을 주는 성분으로 알려져 있다.In addition, astaxanthin has 6,000 times more antioxidant capacity than vitamin C, so it is known as a component that relieves eye fatigue and helps eye health.
뿐만 아니라, 감마 아미노뷰티르산(γ-aminobutyric acid)은 일종의 발효액으로 반려동물의 중추신경계에 작용하여 신경흥분을 억제하고 안정화시키기 위해 첨가된다.In addition, gamma aminobutyric acid (γ-aminobutyric acid) is a kind of fermented liquid that acts on the central nervous system of companion animals to suppress and stabilize nerve excitation.
다른 한편, 본 발명에 따른 반려동물의 눈물 착색예방용 조성물은 브로콜리 스프라우트 분말, 새싹보리 추출물 분말, 산양유(초유 포함) 추출물 분말, 표고버섯균사체 분말, 마리골드 추출물 분말 외에 케일 분말, 고구마 분말, 단호박 분말, 난각분말, 당근 분말 및 올리브유를 유효성분으로 포함할 수 있다. 여기서, 분말은 미세한 가루를 포함하며, 미세한 가루보다는 입자가 커 눈으로 식별할 수 있는 고형물도 포함하는 의미이다.On the other hand, the composition for preventing tear staining of companion animals according to the present invention is broccoli sprout powder, sprout barley extract powder, goat milk (including colostrum) extract powder, shiitake mushroom mycelium powder, marigold extract powder, kale powder, sweet potato powder, Sweet pumpkin powder, egg shell powder, carrot powder, and olive oil may be included as active ingredients. Here, the powder includes fine powder, and is meant to include solids that can be identified with the naked eye because the particles are larger than the fine powder.
이 경우, 추가되는 유효성분은 정제수 100중량부에 대해, 케일 분말 5-10중량부, 고구마 분말 5-10중량부, 단호박 분말 10-12중량부, 난각분말 5-10중량부, 당근 분말 2-5중량부, 올리브유 4-6중량부를 첨가 구성할 수 있다.In this case, the added active ingredients are 5-10 parts by weight of kale powder, 5-10 parts by weight of sweet potato powder, 10-12 parts by weight of sweet pumpkin powder, 5-10 parts by weight of egg shell powder, 2 parts by weight of carrot powder, based on 100 parts by weight of purified water. -5 parts by weight, 4-6 parts by weight of olive oil may be added.
여기에서, 케일 분말은 철분과 엽산이 풍부하여 강아지의 적색 눈물 발생을 억제하는데 기여하며; 고구마 분말은 비타민C와 비타민A가 풍부하여 강아지의 체내 면역력을 높이는데 기여하고 항산화효과를 증진시킨다.Here, kale powder is rich in iron and folic acid, which contributes to inhibiting the development of red tears in puppies; Sweet potato powder is rich in vitamin C and vitamin A, which contributes to increasing the immunity of the dog's body and enhances the antioxidant effect.
그리고, 단호박 분말은 베타카로틴이 다량 함유되어 있어 강아지의 눈 피로를 풀어주고 시력 개선에 기여하며, 안구건조증을 예방하는데 기여한다.In addition, the sweet pumpkin powder contains a large amount of beta-carotene, so it relieves the dog's eye fatigue, contributes to improving eyesight, and contributes to preventing dry eye syndrome.
또한, 난각분말은 칼슘이 풍부하여 눈 건강 증진에 기여하고, 당근 분말은 베타카로틴과 비타민A의 함유량이 많아 눈 건강을 유지하고 시력을 향상시키는데 기여하며, 올리브유는 항산화 효과와 올러유러핀 성분에 의해 눈의 노화를 억제하는 특징이 있다.In addition, egg shell powder is rich in calcium and contributes to eye health, carrot powder is high in beta-carotene and vitamin A, which contributes to maintaining eye health and improving eyesight, and olive oil has antioxidant effects and oleuropein. It has the characteristic of suppressing eye aging by
덧붙여, 상기 정제수 100중량부에 대해, 히알루론산나트륨 20중량부, 카보머 20중량부가 더 첨가될 수 있다.In addition, 20 parts by weight of sodium hyaluronate and 20 parts by weight of carbomer may be further added to 100 parts by weight of the purified water.
이때, 히알루론산나트륨(Sodium hyaluronate)은 D-글루쿠론산과 N-아세틸클루코사민이 반복적으로 결합된 성분으로서, 수분보유 능력이 뛰어난 다당체이다.At this time, sodium hyaluronate is a component in which D-glucuronic acid and N-acetylglucosamine are repeatedly bonded, and is a polysaccharide having excellent water retention ability.
이러한 히알루론산나트륨은 수용성으로서, 눈물층의 수분이 충분히 오랜시간 동안 유지될 수 있도록 하여 안구건조증은 현저히 완화시키게 된다.Sodium hyaluronate is water-soluble, so that the moisture in the tear layer can be maintained for a sufficiently long time, thereby significantly alleviating dry eye syndrome.
그리고, 카보머(Carbomer)는 히알루론산나트륨과 함께 사용하면 미세한 피막을 형성하면서 안구의 건조되지 않도록 건조지연 시간을 지속시킨다.In addition, Carbomer, when used together with sodium hyaluronate, forms a fine film and lasts the drying delay time so that the eyes do not dry out.
또다른 한편, 본 발명에 따른 반려동물의 눈물 착색예방용 조성물은 브로콜리 스프라우트 분말, 새싹보리 추출물 분말, 산양유(초유 포함) 추출물 분말, 표고버섯균사체 분말, 마리골드 추출물 분말, 케일 분말, 고구마 분말, 단호박 분말, 난각분말, 당근 분말 및 올리브유 외에 양배추 분말, 해바라기유, 노루궁뎅이 버섯 우린물을 유효성분으로 더 포함할 수 있다.On the other hand, the composition for preventing tear staining of companion animals according to the present invention is broccoli sprout powder, sprout barley extract powder, goat milk (including colostrum) extract powder, shiitake mushroom mycelium powder, marigold extract powder, kale powder, sweet potato powder In addition to sweet pumpkin powder, egg shell powder, carrot powder, and olive oil, cabbage powder, sunflower oil, and deer's mushroom broth may be further included as active ingredients.
이 경우, 추가되는 유효성분은 정제수 100중량부에 대해, 양배추 분말 3-5중량부, 해바라기유 3-5중량부, 노루궁뎅이 버섯 우린물 5-10중량부를 첨가 구성할 수 있다.In this case, the added active ingredient may be constituted by adding 3-5 parts by weight of cabbage powder, 3-5 parts by weight of sunflower oil, and 5-10 parts by weight of ericium erinaceus mushroom broth based on 100 parts by weight of purified water.
이때, 양배추 분말은 양질의 비타민C를 함유하고 있고, 강력한 항산화 작용에 의해 눈 주변 근육의 처짐을 막아 강아지 눈 병 예방에 도움을 준다.At this time, cabbage powder contains high-quality vitamin C, and its strong antioxidant action prevents the muscles around the eyes from sagging, helping to prevent eye diseases in dogs.
그리고, 해바라기유는 토코페놀을 함유하고 있어 눈 처짐을 방지하고, 눈물 착색현상을 억제하는데 기여한다.In addition, sunflower oil contains tocophenol, which contributes to preventing eye sagging and suppressing tear coloration.
또한, 노루궁뎅이 버섯 우린물은 칼륨과 칼슘 및 마그네슘이 풍부하고 각종 미네랄을 함유하고 있어 특히 곰팡이 및 염증 억제, 면역력 개선, 상처 치유에 효과가 있는 것으로 보고되어 있다. 이는 강아지의 눈을 건강하게 유지시키는데 기여하게 된다.In addition, ericium erinaceus mushroom broth is rich in potassium, calcium and magnesium and contains various minerals, so it is reported to be effective in suppressing mold and inflammation, improving immunity, and healing wounds. This will contribute to keeping your dog's eyes healthy.
이하, 실시예에 대하여 설명한다.Examples will be described below.
[실시예 1][Example 1]
본 발명에 따른 조성물을 강아지에 급여하여 눈물 착색 면적이 감소하는지 여부를 측정하는 실험을 실시하였고, 대상 강아지에 대한 사진은 도 1에 도시하였다.An experiment was conducted to measure whether or not the tear staining area was reduced by feeding the composition according to the present invention to puppies, and a photograph of the target puppies was shown in FIG.
대상 강아지는 도 1에서 좌측부터 강아지1,2,3,4,5,6,7로 명명하였으며, 강아지1은 비숑프리제, 강아지2는 스피츠, 강아지3은 포메라니안, 강아지4는 포메라니안, 강아지5는 비숑프리제, 강아지6은 포메라니안, 강아지7 푸들로 대중적으로 인지도가 높고 눈물착색으로 사례가 많이 발생하는 견종으로 선택했다.The target puppies are named puppies 1, 2, 3, 4, 5, 6, and 7 from the left in FIG. 1, Puppy 1 is Bichon Frize, Puppy 2 is Spitz, Puppy 3 is Pomeranian, Puppy 4 is Pomeranian, and Puppy 5 is Bichon Frize, Puppy 6 is a Pomeranian, and Puppy 7 is a poodle, which is popularly known and has been selected as a breed with many cases of tear staining.
본 발명에 따른 급여 전에 강아지1-7에 대한 육안상 붉은색 혹은 적갈색으로 침착된 부위를 측정하여 눈물 착색면적으로 판단하였다.Before feeding according to the present invention, the areas visually deposited in red or reddish brown on puppies 1-7 were measured to determine the tear staining area.
그리고, 10주간 하루에 2번(오전 9시, 오후 2시) 급여하였고, 각각 주간에 한 번 눈물 착색 정도를 착색 면적별로 측정하였다.In addition, they were fed twice a day (9:00 am and 2:00 pm) for 10 weeks, and the degree of tear staining was measured for each colored area once a week.
아울러, 측정 결과는 아래 표 1에 나타내었다.In addition, the measurement results are shown in Table 1 below.
상기 표 1은 반려동물용 눈 건강 유지 및 눈물 착색예방 위한 조성물을 급여에 따른 눈물 착색 면적의 감소 수치를 보여 준다.Table 1 shows the decrease in tear staining area according to feeding the composition for maintaining eye health and preventing tear staining for companion animals.
표 1에 따르면, 급여 후 눈물 착색 면적이 모두 감소했음을 확인할 수 있었고, 10주 후에는 모두 정상 범위로 들어 왔음을 확인하였다.According to Table 1, it was confirmed that all the areas of tear staining after feeding were reduced, and after 10 weeks, it was confirmed that they all returned to the normal range.
[실시예 2][Example 2]
본 발명에 따른 조성물을 급여한 강아지1-7의 눈 주변 습윤면적 감소여부를 측정하였다.The decrease in wet area around the eyes of puppies 1-7 fed with the composition according to the present invention was measured.
실시예1과 같이 10주간 급여하면서 강아지2,3,4,7에 대해서는 눈 주변 털의 습윤 정도를 거즈로 닦아내어 축축해지는 면적, 점도, 착색강도를 확인하였다.As in Example 1, while feeding for 10 weeks, for puppies 2, 3, 4, and 7, the wetness level of the fur around the eyes was wiped with gauze to check the wet area, viscosity, and coloration strength.
확인 결과, 도 2 및 표 2와 같이 강아지2,3,4,7 모두 면적, 점도, 착색강도가 감소하였다.As a result of confirmation, as shown in FIG. 2 and Table 2, the area, viscosity, and coloration intensity of puppies 2, 3, 4, and 7 decreased.
상기 표 2와 그래프는 본 발명에 따른 조성물 급여에 의한 눈물 습윤 감소상태를 보인 것이다.Table 2 and the graph show the reduced state of tear wetting by feeding the composition according to the present invention.
[실시예 3][Example 3]
본 발명에 따른 조성물을 급여한 강아지1-7의 눈 건강 상태를 측정하였다.Eye health of puppies 1-7 fed with the composition according to the present invention was measured.
실시예1과 동일하게 진행하면서 강아지1-7에 대해 눈 건강 상태, 질병여부를 수의사가 직접 일일이 관찰하였고, 이를 10주간 기록한 후 평균을 내었다. 이때, 척도는 5점:매우좋음, 4점:좋음, 3점:보통, 2점:나쁨, 1점:매우나쁨으로 평가하였다.In the same manner as in Example 1, the veterinarian personally observed the eye health status and disease status of puppies 1-7, recorded them for 10 weeks, and then averaged them. At this time, the scale was evaluated as 5 points: very good, 4 points: good, 3 points: average, 2 points: bad, and 1 point: very bad.
이때, 비교를 위해 본 발명에 따른 조성물을 급여하지 않은 강아지(강아지1-5와 대응되는 종류)에 대해서도 동일하게 관찰하고 평가 기록하였으며, 이를 아래 표 3에 나타내었다.At this time, for comparison, the same observation and evaluation were recorded for puppies (types corresponding to puppies 1-5) that did not feed the composition according to the present invention, which are shown in Table 3 below.
평가결과, 본 발명에 따른 조성물을 급여한 강아지가 그렇지 않은 강아지에 비해 눈 상태도 더 건강하였고, 눈병 발명 확률도 감소하는 것으로 확인되었다.As a result of the evaluation, it was confirmed that the puppies fed the composition according to the present invention had a healthier eye condition than the puppies that did not, and the probability of developing an eye disease was also reduced.
즉, 표 3에서 눈 건강 상태와 눈 질병 발명우려의 점수가 높을 수록 눈이 건강한 상태이고, 질병 발명 우려가 낮다는 것을 의미한다.That is, in Table 3, the higher the score of the eye health state and the fear of inventing an eye disease, the higher the eye condition and the lower the fear of developing a disease.
이로써, 본 발명에 따른 조성물을 반려동물, 특히 강아지의 눈 건강 급여로 사용할 수 있음을 확인하였기에 보다 저렴하고 우수한 제품으로 시판할 수 있을 것으로 기대된다.Accordingly, since it was confirmed that the composition according to the present invention can be used as an eye health benefit for companion animals, especially dogs, it is expected that it will be marketed as a cheaper and superior product.
Claims (4)
상기 산양유 추출물에 류신과 감마리놀렌산을 더 함유시키되, 상기 산양유 추출물 100중량부를 기준으로 류신 5.5중량부 및 감마리놀렌산 3.5중량부를 각각 더 첨가혼합하고;
상기 정제수 100중량부에 대해, 메틸살리실레이트 10중량부, N-아세틸글루코사민 15중량부를 더 첨가하고,
상기 브로콜리 스프라우트 분말 100중량부에 대해, 카르복시메틸 셀룰로오스나트륨 10중량부, 글리세린지방산에스테르 10중량부, 뜨레할로스액 5중량부, 징코라이드 5중량부, 아스타잔틴 2.5중량부, 감마 아미노뷰티르산 3.5중량부를 더 첨가한 것을 특징으로 하는 반려동물의 눈물 착색예방용 조성물.
According to claim 1,
Leucine and gamma-linolenic acid are further contained in the goat milk extract, and 5.5 parts by weight of leucine and 3.5 parts by weight of gamma-linolenic acid are further added and mixed based on 100 parts by weight of the goat milk extract;
Based on 100 parts by weight of the purified water, 10 parts by weight of methyl salicylate and 15 parts by weight of N-acetylglucosamine were further added,
Based on 100 parts by weight of the broccoli sprout powder, 10 parts by weight of sodium carboxymethyl cellulose, 10 parts by weight of glycerin fatty acid ester, 5 parts by weight of trehalose solution, 5 parts by weight of zincolide, 2.5 parts by weight of astaxanthin, gamma aminobeauty A composition for preventing tear staining of companion animals, characterized in that 3.5 parts by weight of ric acid is further added.
상기 정제수 100중량부에 대해, 케일 분말 5-10중량부, 고구마 분말 5-10중량부, 단호박 분말 10-12중량부, 난각분말 5-10중량부, 당근 분말 2-5중량부, 올리브유 4-6중량부가 더 첨가 구성된 것을 특징으로 하는 반려동물의 눈물 착색예방용 조성물.According to claim 1,
Based on 100 parts by weight of the purified water, 5-10 parts by weight of kale powder, 5-10 parts by weight of sweet potato powder, 10-12 parts by weight of sweet pumpkin powder, 5-10 parts by weight of egg shell powder, 2-5 parts by weight of carrot powder, 4 olive oil A composition for preventing tear staining of companion animals, characterized in that 6 parts by weight are further added.
상기 정제수 100중량부에 대해, 양배추 분말 3-5중량부, 해바라기유 3-5중량부, 노루궁뎅이 버섯 우린물 5-10중량부를 더 첨가한 것을 특징으로 하는 반려동물의 눈물 착색예방용 조성물.According to claim 3,
A composition for preventing tear staining of companion animals, characterized in that 3-5 parts by weight of cabbage powder, 3-5 parts by weight of sunflower oil, and 5-10 parts by weight of ericium erinaceus mushroom broth are further added to 100 parts by weight of the purified water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220139093A KR102513994B1 (en) | 2022-10-26 | 2022-10-26 | Composition for preventing tear staining of companion animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220139093A KR102513994B1 (en) | 2022-10-26 | 2022-10-26 | Composition for preventing tear staining of companion animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102513994B1 true KR102513994B1 (en) | 2023-03-24 |
Family
ID=85872815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220139093A KR102513994B1 (en) | 2022-10-26 | 2022-10-26 | Composition for preventing tear staining of companion animals |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102513994B1 (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011037891A (en) * | 2002-09-30 | 2011-02-24 | Mark A Babizhayev | Use of aqueous ophthalmic composition for producing pharmaceutical composition and aqueous ophthalmic composition |
| KR20150014966A (en) * | 2012-05-15 | 2015-02-09 | 에프. 홀저 게엠베하 | Ophthalmological vehicle system for drugs |
| KR20170045247A (en) * | 2014-08-29 | 2017-04-26 | 와카모토 세이야꾸 가부시끼가이샤 | Lactic acid bacteria-containing composition |
| KR20170142520A (en) * | 2016-06-17 | 2017-12-28 | 주식회사 이노벳 | Companion animal ophthalmology disease management assistance nutrient and the manufacture Method |
| KR20190050667A (en) * | 2017-11-03 | 2019-05-13 | (주) 노바렉스 | Composition for anti-oxidation or anti-inflammation comprising barley sprouts extract as an active ingredient |
| KR102220535B1 (en) * | 2019-01-28 | 2021-02-24 | 심근훈 | Manufacturing Method of Feed Composition for dogs and Feed Composition Manufactured by the Same |
| KR102409377B1 (en) | 2020-06-30 | 2022-06-17 | (주)에이앤바이오 | Composition for improving dry eyes and preventing tear pigmentation for pets |
| KR102420268B1 (en) * | 2022-03-17 | 2022-07-13 | 박종호 | Nutritional composition for improving eye health for companion animals |
| KR102432959B1 (en) * | 2022-02-14 | 2022-08-18 | 주식회사 스위피 | Nutritional Composition for Companion Animals and Nutritional Supplements for Companion Animals |
| KR20220120844A (en) * | 2021-02-24 | 2022-08-31 | 이노베이션허브(주) | Herbal composition for preventing and treating tear stain and excessive tear in companion animals |
-
2022
- 2022-10-26 KR KR1020220139093A patent/KR102513994B1/en active IP Right Grant
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011037891A (en) * | 2002-09-30 | 2011-02-24 | Mark A Babizhayev | Use of aqueous ophthalmic composition for producing pharmaceutical composition and aqueous ophthalmic composition |
| KR20150014966A (en) * | 2012-05-15 | 2015-02-09 | 에프. 홀저 게엠베하 | Ophthalmological vehicle system for drugs |
| KR20170045247A (en) * | 2014-08-29 | 2017-04-26 | 와카모토 세이야꾸 가부시끼가이샤 | Lactic acid bacteria-containing composition |
| KR20170142520A (en) * | 2016-06-17 | 2017-12-28 | 주식회사 이노벳 | Companion animal ophthalmology disease management assistance nutrient and the manufacture Method |
| KR20190050667A (en) * | 2017-11-03 | 2019-05-13 | (주) 노바렉스 | Composition for anti-oxidation or anti-inflammation comprising barley sprouts extract as an active ingredient |
| KR102220535B1 (en) * | 2019-01-28 | 2021-02-24 | 심근훈 | Manufacturing Method of Feed Composition for dogs and Feed Composition Manufactured by the Same |
| KR102409377B1 (en) | 2020-06-30 | 2022-06-17 | (주)에이앤바이오 | Composition for improving dry eyes and preventing tear pigmentation for pets |
| KR20220120844A (en) * | 2021-02-24 | 2022-08-31 | 이노베이션허브(주) | Herbal composition for preventing and treating tear stain and excessive tear in companion animals |
| KR102432959B1 (en) * | 2022-02-14 | 2022-08-18 | 주식회사 스위피 | Nutritional Composition for Companion Animals and Nutritional Supplements for Companion Animals |
| KR102420268B1 (en) * | 2022-03-17 | 2022-07-13 | 박종호 | Nutritional composition for improving eye health for companion animals |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20120085240A (en) | Natural and sustainable seaweed formula that replaces synthetic additives in fish feed | |
| KR102420268B1 (en) | Nutritional composition for improving eye health for companion animals | |
| US20050255147A1 (en) | Composition for dietary enrichment | |
| JP2009538353A (en) | Composition for promoting eye health | |
| CN110786424A (en) | Application of magnolol and/or honokiol in poultry breeding | |
| WO2019166418A1 (en) | Nutraceutical or pharmaceutical composition | |
| KR100647067B1 (en) | Feed composition comprising Rubus coreanus for poultry and the egg produced by feeding the same | |
| CN101147527B (en) | Feed capable of leading duck egg to have softening blood vessel and reducing blood pressure function and preparation method | |
| KR20210017464A (en) | Nutritional supplements composition having antiinflammatory activity for pet comprising morinda citrifolia and method thereof | |
| CN106616037A (en) | Taurine compound preparation for groupers and application thereof | |
| Bunyan et al. | Vitamin E and stress: 8.* Nutritional effects of dietary stress with silver in vitamin E-deficient chicks and rats | |
| CA2910568C (en) | Method for improving mineral resorption in farmed fish and crustacean | |
| KR102513994B1 (en) | Composition for preventing tear staining of companion animals | |
| JP2020015672A (en) | Skin anti-aging agent and anti-aging related gene expression regulating agent | |
| CN1850065A (en) | Use of oral conjugated linoleic acid and its derivative for increasing muscule and skin beauty | |
| CN105558435A (en) | Feed additive for preventing and treating silver carp hemorrhagic disease | |
| KR102457595B1 (en) | Composion and methods for promoting the growth and increasing the immunity of animals | |
| CN102845362A (en) | Feeding method of special selenium-enriched chickens for Doukou roast chicken | |
| JP3131917U (en) | Soft capsule | |
| KR102564832B1 (en) | Composition for preventing hair loss in companion animals | |
| CN109770117A (en) | A kind of freshwater shrimp feed and preparation method thereof | |
| KR20200098968A (en) | Quail Breeding Method | |
| Bartov et al. | Nutritional factors affecting the occurrence of experimental encephalomalacia in chicks | |
| KR102470109B1 (en) | Composition feed supplements of companion animal and soft capsule comprising the same | |
| CN108813155A (en) | A kind of feed addictive and the preparation method and application thereof improving immunity of layer chicken, egg feedstuff |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |